respiratori
failur
major
complic
patient
hospit
sever
viral
infect
influenza
sever
acut
respiratori
syndrom
sar
novel
coronaviru
cov
infect
affect
patient
may
progress
rapidli
acut
respiratori
distress
syndrom
ard
excess
cytokin
chemokin
respons
propos
central
diseas
pathogenesi
damag
dysregul
respons
mark
elev
blood
observ
patient
infect
avian
influenza
viru
respons
correl
high
level
viral
replic
respiratori
higher
plasma
level
proinflammatori
observ
patient
sever
infect
mild
diseas
level
correl
extent
progress
neuraminidas
inhibitor
nai
therapi
use
improv
clinic
outcom
administ
patient
hospit
influenza
within
day
ill
onset
often
delay
initi
nai
therapi
progress
diseas
sometim
occur
despit
earli
sar
mark
increas
cytokin
interferon
ifn
inflammatori
cytokin
chemokin
chang
confirm
activ
immun
cmi
hyperinn
inflammatori
respons
accumul
monocytesmacrophag
articl
review
potenti
role
adjunct
therapi
immunomodul
agent
manag
patient
hospit
sever
influenza
acut
respiratori
viral
infect
although
focu
clinic
report
anim
model
studi
relev
also
highlight
year
number
random
control
trial
rct
suggest
system
corticosteroid
may
improv
clinic
outcom
hospit
length
stay
patient
hospit
commun
acquir
pneumonia
cap
howev
must
point
studi
recruit
patient
predominantli
bacteri
cap
receiv
appropri
antibiot
therapi
contain
infect
favor
result
follow
addit
system
corticosteroid
gener
cap
viral
increas
data
indic
system
corticosteroid
may
lead
advers
outcom
patient
hospit
sever
influenza
especi
delay
commenc
effect
antivir
therapi
prospect
observ
studi
assess
viral
load
durat
viral
shed
adult
hospit
season
influenza
administr
system
corticosteroid
acut
exacerb
either
asthma
copd
found
independ
risk
factor
associ
prolong
viral
shed
beyond
week
ill
retrospect
review
conduct
nation
hospit
japan
patient
influenza
gener
receiv
nai
within
day
ill
onset
administr
system
corticosteroid
pneumonia
acut
wheez
associ
wors
outcom
compar
receiv
howev
mani
observ
studi
shown
earli
use
system
corticosteroid
therapi
especi
absenc
nai
therapi
nai
initi
beyond
day
ill
onset
associ
increas
risk
death
increas
rate
nosocomi
pneumonia
increas
risk
develop
critic
diseas
patient
hospit
pneumonia
andor
wherea
studi
shown
surviv
advantag
compar
icu
patient
without
addit
system
corticosteroid
tabl
major
outbreak
sar
plasma
concentr
first
week
independ
prognost
factor
odd
ratio
advers
outcom
icu
admiss
death
ci
per
fold
increas
plasma
concentr
median
wherea
increas
lung
tissu
patient
die
system
corticosteroid
given
patient
effort
dampen
immunopatholog
host
respons
activ
cmi
hyperinn
inflammatori
hong
kong
mainland
china
progress
respiratori
failur
sar
patient
associ
comput
tomograph
histopatholog
evid
bronchiol
obliteran
organ
use
system
corticosteroid
associ
seemingli
favor
clinic
immunolog
respons
evidenc
mark
reduct
concentr
day
treatment
p
patient
hospit
howev
rct
compar
earli
use
intraven
system
corticosteroid
versu
normal
salin
control
patient
hospit
sar
plasma
rna
concentr
much
higher
second
third
week
ill
former
suggest
system
steroid
might
prolong
invas
aspergillosi
fatal
outcom
report
patient
higher
rate
pneumonia
vap
sar
period
sar
addit
increas
risk
complic
likewis
invas
aspergillosi
fatal
outcom
also
occur
patient
influenza
infect
receiv
system
corticosteroid
rct
found
system
corticosteroid
associ
delay
viral
clearanc
rsv
rhinoviru
experi
caution
use
system
corticosteroid
patient
sever
viral
pneumonia
recommend
use
system
corticosteroid
eg
hydrocortison
mg
h
refractori
septic
shock
relat
sever
influenza
includ
avian
influenza
retrospect
analysi
suggest
earli
administr
convalesc
blood
product
variou
type
might
reduc
risk
death
patient
influenza
pneumonia
pandem
especi
given
treatment
within
day
pneumonia
retrospect
review
found
addit
convalesc
plasma
donat
sar
patient
recov
ill
sar
patient
progress
diseas
led
higher
day
discharg
rate
among
patient
n
given
convalesc
plasma
versu
p
lower
mortal
versu
p
compar
histor
control
n
anoth
review
show
higher
day
discharg
rate
versu
p
among
sar
patient
given
convalesc
plasma
day
ill
n
receiv
convalesc
plasma
day
n
among
pcr
posit
seroneg
time
plasma
infus
versu
p
convalesc
plasma
also
use
favor
respons
patient
sever
avian
influenza
pneumonia
respond
oseltamivir
prospect
multicent
studi
hong
kong
shown
one
dose
convalesc
plasma
neutral
antibodi
titer
appear
effect
reduc
mortal
respiratori
tract
viral
load
serum
level
cytokin
patient
sever
infect
requir
intens
care
support
compar
recent
rct
involv
patient
hospit
sever
infect
hong
kong
compar
adjunct
treatment
hyperimmun
globulin
n
prepar
convalesc
plasma
person
recov
diseas
normal
ivig
manufactur
control
n
hyperimmun
globulin
group
significantli
lower
day
viral
load
wherea
multivari
analysi
patient
n
receiv
either
therapi
within
day
symptom
onset
found
hyperimmun
globulin
treatment
factor
independ
reduc
mortal
ci
p
antioxid
nac
shown
inhibit
influenza
product
molecul
lung
epitheli
cell
infect
highli
pathogen
influenza
nac
mgkg
continu
iv
infus
daili
appear
effect
reduc
crp
oxygen
requir
improv
clinic
outcom
one
previous
healthi
woman
sever
pneumonia
septic
shock
due
howev
interpret
efficaci
nac
limit
concomit
use
oseltamivir
mg
bd
murin
model
lethal
influenza
infect
primari
endpoint
day
surviv
nac
alon
achiev
surviv
rate
wherea
surviv
increas
oseltamivir
oseltamivir
nac
use
studi
vitro
effect
nac
modul
releas
alveolar
type
ii
cell
infect
influenza
strain
b
rsv
nac
inhibit
replic
three
signific
induct
strongli
inhibit
nac
express
releas
level
nac
also
reduc
intracellular
hydrogen
peroxid
concentr
restor
intracellular
total
thiol
content
mechan
nac
includ
inhibit
transloc
cellular
nucleu
phosphoryl
mapk
studi
support
research
explor
role
antioxid
amelior
inflammatori
effect
differ
viral
infect
polymyxin
fiber
column
first
develop
japan
hemoperfus
devic
could
remov
endotoxin
hypercytokinemia
due
ill
report
treat
effect
polymyxin
fiber
column
hemoperfus
seemingli
favor
clinic
outcom
year
old
girl
initi
respond
inhal
dri
powder
zanamivir
mg
bd
howev
interpret
effect
polymyxin
fiber
column
hemoperfus
confound
concomit
use
oseltamivir
mg
bd
sivelestat
inhibitor
human
neutrophil
elastas
pediatr
case
seri
suggest
may
role
therapeut
plasma
exchang
tpe
strategi
cytokin
attenu
sever
shock
acut
lung
injuri
relat
influenza
respond
standard
intens
care
three
children
age
year
ard
hemodynam
compromis
requir
invas
mechan
ventil
inhal
nitric
oxid
one
receiv
membran
oxygen
tpe
provid
rescu
strategi
three
exchang
mlkg
consecut
day
subsequ
three
patient
dramat
reduct
pediatr
logist
organ
dysfunct
score
surviv
good
function
hong
et
analyz
intraven
immunoglobulin
ivig
sera
kawasaki
diseas
patient
receiv
ivig
microneutr
hemagglutin
inhibit
antibodi
six
differ
ivig
prepar
test
signific
level
antibodi
concentr
gdl
immunoglobulin
wherea
sera
kawasaki
diseas
patient
signific
increas
antibodi
receiv
gkg
ivig
administ
patient
ard
due
favor
respons
interpret
data
limit
concomit
use
signific
neutral
activ
influenza
virus
observ
human
ivig
lot
manufactur
aggreg
observ
suggest
evalu
specif
neutral
antibodi
titer
may
provid
use
inform
ivig
potenti
therapeut
rais
possibl
use
ivig
therapi
sever
andor
influenza
viru
infect
especi
import
note
ivig
may
increas
blood
viscos
henc
risk
thromboembol
diseas
occur
treatment
sar
despit
use
prophylact
statin
immunomodul
effect
eg
repress
induct
subsequ
activ
potenti
role
propos
treatment
prophylaxi
pandem
influenza
base
observ
studi
show
surviv
benefit
patient
receiv
statin
develop
bacteremia
sepsi
howev
murin
model
influenza
infect
administr
rosuvastatin
effect
viral
clearanc
influenza
infect
mortal
studi
balbc
mice
treat
sever
type
statin
intraperiton
oral
variou
concentr
infect
influenza
viru
influenza
viru
influenza
viru
influenza
viru
influenza
viru
improv
surviv
compar
mice
receiv
differ
type
statin
variou
dose
untreat
cohort
studi
influenza
season
ontario
canada
match
shown
small
protect
effect
chronic
use
statin
pneumonia
hospit
ci
pneumonia
mortal
ci
mortal
ci
furthermor
protect
effect
attenu
substanti
multivari
adjust
exclud
multipl
observ
individu
declin
time
differ
across
propens
score
quintil
risk
group
unchang
season
retrospect
studi
use
uk
influenza
clinic
inform
network
databas
patient
hospit
confirm
influenza
infect
apr
jan
statist
signific
associ
statin
use
sever
outcom
found
age
year
adjust
ci
n
adjust
age
sex
obes
indic
statin
associ
statin
use
sever
outcom
statist
anoth
studi
hospit
adult
influenza
season
ten
state
usa
analyz
evalu
associ
receiv
statin
death
statin
treatment
prior
hospit
associ
protect
adjust
odd
death
ci
adjust
age
race
comorbid
diseas
influenza
vaccin
antivir
administr
multivari
logist
regress
current
rct
data
acut
use
statin
acut
manag
sever
influenza
sever
viral
infect
one
rct
found
acut
administr
oral
pravastatin
mg
benefici
reduc
frequenc
vap
icu
patient
bronchiol
due
respiratori
syncyti
viru
rsv
treatment
clarithromycin
benefici
effect
durat
hospit
durat
supplement
oxygen
need
bronchodil
treatment
addit
signific
reduct
plasma
eotaxin
level
follow
week
treatment
moreov
readmiss
hospit
within
month
discharg
significantli
lower
clarithromycin
clarithromycin
shown
reduc
viral
titer
cytokin
supernat
fluid
viral
rna
cell
suscept
viru
infect
cultur
human
tracheal
epitheli
cell
infect
influenza
viru
addit
reduc
express
sialic
acid
gal
human
tracheal
mucos
surfac
number
fluoresc
intens
acid
endosom
cell
viral
rnp
enter
observ
studi
assess
mix
bag
immunomodul
agent
macrolid
system
corticosteroid
statin
develop
sever
diseas
hospit
adult
none
therapi
found
associ
lower
risk
develop
sever
rct
young
patient
mild
season
influenza
infect
receiv
earli
nai
therapi
japan
addit
clarithromycin
result
better
outcom
shorter
durat
cough
patient
without
cough
onset
prospect
observ
multicent
studi
patient
primari
viral
pneumonia
due
conduct
across
icu
spain
treatment
n
associ
improv
surviv
critic
ill
patient
primari
viral
recent
tennesse
medicaid
cohort
studi
found
day
azithromycin
therapi
associ
small
absolut
increas
cardiovascular
death
especi
among
patient
high
baselin
risk
cardiovascular
nevertheless
data
need
role
macrolid
patient
hospit
sever
influenza
judg
potenti
valu
gemfibrozil
agonist
inhibit
product
cytokin
addit
clinic
use
activ
increas
surviv
balbc
mice
alreadi
ill
infect
influenza
viru
gemfibrozil
administ
intraperiton
daili
day
intranas
exposur
viru
surviv
increas
mice
n
mice
given
gemfibrozil
mgkgday
n
p
studi
examin
impact
system
corticosteroid
dexamethason
agonist
pioglitazon
outcom
infect
mice
mice
expos
room
air
cigarett
smoke
day
inocul
viru
mimic
influenza
copd
mice
shown
exacerb
inflammatori
respons
follow
infect
dexamethason
reduc
mononuclear
cell
lavag
bal
viral
infect
mice
wherea
pioglitazon
reduc
mononuclear
cell
neutrophil
bal
increas
peripher
studi
mice
challeng
virul
influenza
virus
includ
avian
strain
increas
accumul
dendrit
cell
dc
subset
known
tip
dc
observ
airway
mice
pneumonia
studi
found
treatment
pioglitazon
reduc
tipdc
traffick
suggest
might
moder
potenti
lethal
consequ
excess
tipdc
recruit
without
abrog
expans
compromis
viru
carboxamid
ribonucleotid
aicar
activ
ampk
known
stimul
ppar
complement
action
immunosuppress
pharmacolog
ppar
mice
infect
influenzaapuerto
viru
rosiglitazon
treatment
provid
absolut
protect
death
wherea
mice
treat
pioglitazon
display
increas
surviv
control
anim
aicar
alon
provid
increas
protect
wherea
aicarpioglitazon
combin
increas
surviv
result
suggest
addit
benefit
use
two
drug
studi
suggest
role
agonist
explor
manag
sever
viral
exacerb
studi
influenza
viral
infect
wild
type
cyclooxygenas
cox
defici
defici
mice
shown
defici
result
greater
morbid
inflamm
wherea
defici
led
reduc
morbid
inflamm
mortal
influenza
infect
howev
treatment
inhibitor
influenza
viral
infect
mice
model
detriment
host
wherea
inhibit
celecoxib
significantli
modul
diseas
intro
studi
shown
inhibitor
suppress
viru
replic
human
macrophag
result
suggest
viru
replic
depend
activ
signal
pathway
host
role
delay
antivir
combin
immunomodul
therapi
test
balbc
mice
challeng
avian
influenza
signific
improv
surviv
rate
surviv
time
note
group
treat
hour
viral
challeng
tripl
combin
zanamivir
celecoxib
mesalazin
versu
zanamivir
alon
addit
significantli
higher
level
lymphocyt
less
pulmonari
inflamm
found
group
receiv
tripl
therapi
mesalazin
inhibit
lipoxygenas
cox
pathway
lead
reduct
cytokin
eicosanoid
therefor
reduc
activ
inflammatori
cell
macrophag
neutrophil
mesalazin
also
inhibit
activ
promot
synthesi
phosphatid
acid
thu
inhibit
stimulatori
effect
ceramid
apoptosi
clinic
studi
need
therapeut
role
two
agent
immunomodul
properti
sever
influenza
viral
infect
summari
convalesc
plasma
appear
use
safe
adjunct
therapi
sar
influenza
influenza
limit
avail
time
administr
evalu
specif
neutral
antibodi
titer
ivig
sever
andor
influenza
viru
infect
need
especi
immunocompromis
system
corticosteroid
use
routin
sever
viral
infect
influenza
may
increas
risk
mortal
morbid
eg
secondari
infect
especi
delay
lack
effect
antivir
therapi
worthwhil
explor
immunomodul
efficaci
nac
macrolid
acut
use
statin
ppar
agonist
ampk
celecoxib
mesalazin
anim
detail
human
observ
studi
prefer
rct
role
plasmapheresi
hemoperfus
rescu
therapi
also
interest
author
compet
interest
declar
